Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.

Autor: Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI, Morris, Michael J

Publikováno v: Journal of Clinical Oncology; 5/20/2009, Vol. 27 Issue 15, p2436-2442, 7p

Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).

Autor: Hussain M; Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Kocherginsky M; Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Agarwal N; Medicine, Huntsman Cancer Institute, Salt Lake City, Utah., Adra N; Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana., Zhang J; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida., Paller CJ; Oncology, Johns Hopkins University, Baltimore, Maryland., Picus J; Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri., Reichert ZR; Division of Hematology/Oncology, Internal Medicine, University of Michigan, Ann Arbor, Michigan., Szmulewitz RZ; Department of Medicine, University of Chicago, Chicago, Illinois., Tagawa ST; Hematology & Medical Oncology, Weill Cornell Medicine, New York, New York., Kuzel TM; Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Bazzi LA; Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Daignault-Newton S; Urology, University of Michigan, Ann Arbor, Michigan., Whang YE; Medicine, Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Dreicer R; Medicine, University of Virginia, Charlottesville, Virginia., Stephenson RD; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey., Rettig MB; Department of Urology, School of Medicine, University of California Los Angeles, Los Angeles, California., Shevrin D; Medical Oncology, NorthShore University Health System, Evanston, Illinois., Gerke T; The Prostate Cancer Clinical Trials Consortium, New York, New York., Chinnaiyan AM; Pathology, University of Michigan, Ann Arbor, Michigan., Antonarakis ES; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 01; Vol. 30 (19), pp. 4318-4328.

Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?

Autor: Cahill EM; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA., Pfail JL; Division of Urologic Oncology, Department of Surgery, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ, 08903-2681, USA., Fu MZ; Division of Urologic Oncology, Department of Surgery, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ, 08903-2681, USA., Saraiya B; Division of Medical Oncology, Department of Medicine, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA., Mayer T; Division of Medical Oncology, Department of Medicine, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA., Stephenson RD; Division of Medical Oncology, Department of Medicine, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA., Ennis RD; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA., Hathout L; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA., Deek MP; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA., Ghodoussipour S; Division of Urologic Oncology, Department of Surgery, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ, 08903-2681, USA., Jang TL; Division of Urologic Oncology, Department of Surgery, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ, 08903-2681, USA. jangtl@cinj.rutgers.edu.

Publikováno v: Current urology reports [Curr Urol Rep] 2023 Jul; Vol. 24 (7), pp. 299-306. Date of Electronic Publication: 2023 Apr 05.

Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.

Autor: Autio KA; Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York., Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ

Publikováno v: Cancer [Cancer] 2013 Sep 01; Vol. 119 (17), pp. 3186-94. Date of Electronic Publication: 2013 Jun 13.

Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

Autor: Morris MJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. morrism@mskcc.org, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI

Publikováno v: European urology [Eur Urol] 2009 Aug; Vol. 56 (2), pp. 237-44. Date of Electronic Publication: 2009 Apr 03.